PCM
ESPR

Pentwater Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Pentwater Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-150,000
Closed -$3.17M – 251
2021
Q2 		$3.17M Buy
+150,000
New +$3.61M 0.03% 127
2019
Q1 		– Sell
-620,400
Closed -$28.5M – 150
2018
Q4 		$28.5M Sell
620,400
-479,600
-44% -$23.1M 0.24% 34
2018
Q3 		$48.8M Buy
1,100,000
+765,300
+229% +$35.1M 0.41% 26
2018
Q2 		$13.1M Buy
+334,700
New +$16.9M 0.1% 60
2017
Q2 		– Sell
-100,000
Closed -$3.53M – 107
2017
Q1 		$3.53M Buy
+100,000
New +$2.29M 0.04% 71

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return